Casandra
Casandra Test Code TA20151Version 1 (DRAFT)
Performing Lab
Lab Tempus AILab Test ID N/A
Tempus Immune Profile Score (IPS)
Clinical Use
Order TestUse
The Tempus Immune Profile Score (IPS) is used as a prognostic indicator for adult patients with metastatic and/or stage IV pan-solid tumor disease who are candidates for immune checkpoint inhibitor (ICI) therapy. It classifies patients into IPS-High or IPS-Low groups, with IPS-High patients showing a higher overall survival when treated with ICI-based regimens.
Special Instructions
Not provided.
Limitations
IPS is relevant for prostate, lung, colorectal, renal, and other major cancer types associated with ICI treatments. It's validated for PD-L1, TMB, and MSI statuses but doesn't replace existing diagnostic methodologies entirely.
Test Details
Methodology
NGS
Biomarkers
Targets not provided.
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen Requirements
Not provided.
Similar Tests
Other tests from different labs that may be relevant
PD‑L1 22C3 IHC with Tumor Proportion Score (TPS) Interpretation, pembrolizumab (KEYTRUDA) and cemiplimab‑rwlc (LIBTAYO)
ARUP Laboratories
PD‑L1 22C3 IHC with Combined Positive Score (CPS) Interpretation, pembrolizumab (KEYTRUDA)
ARUP Laboratories
OmniSeq® INSIGHT
Labcorp
Solid Tumor Expanded Panel
Quest Diagnostics
MI Profile
Caris Life Sciences
PD‑L1 Lung (Atezolizumab), IHC
Quest Diagnostics
Solid Tumor Core Panel
Quest Diagnostics
PD-L1 Quantitative by IHC
Labcorp
PD-L1 (SP142)
MPLN
Programmed Death-Ligand 1 (PD-L1) (SP142), Semi-Quantitative Immunohistochemistry, Manual
Mayo Clinic Lab